...
首页> 外文期刊>Vaccine >Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration
【24h】

Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration

机译:在全身和粘膜给药后,通过新型基于核壳纳米球和微球的疫苗制剂诱导体液和增强的细胞免疫应答

获取原文
获取原文并翻译 | 示例
           

摘要

Anionic surfactant-free polymeric core-shell nanospheres and microspheres were previously described with an inner core constituted by poly(methylmethacrylate) (PMMA) and a highly hydrophilic outer shell composed of a hydrosoluble co-polymer (Eudragit L100-55). The outer shell is tightly linked to the core and bears carboxylic groups capable of adsorbing high amounts (antigen loading ability of up to 20%, w/w) of native basic proteins, mainly by electrostatic interactions, while preserving their activity. In the present study we have evaluated in mice the safety and immunogenicity of new vaccine formulations composed of these nano- and microspheres and the HIV-1 Tat protein. Vaccines were administered by different routes, including intramuscular, subcutaneous or intranasal and the results were compared to immunization with Tat alone or with Tat delivered with the alum adjuvant. The data demonstrate that the nano- and microspheres/Tat formulations are safe and induce robust and long-lasting cellular and humoral responses in mice after systemic and/or mucosal immunization. These delivery systems may have great potential for novel Tat protein-based vaccines against HIV-1 and hold promise for other protein-based vaccines.
机译:先前描述了不含阴离子表面活性剂的聚合物核-壳纳米球和微球,其内核由聚甲基丙烯酸甲酯(PMMA)构成,高度亲水的外壳由水溶性共聚物(Eudragit L100-55)组成。外壳与核紧密连接,并带有羧基,这些羧基能够主要通过静电相互作用吸附大量的天然碱性蛋白质(抗原负载能力高达20%,w / w),同时保留其活性。在本研究中,我们已经在小鼠中评估了由这些纳米球和微球以及HIV-1 Tat蛋白组成的新疫苗制剂的安全性和免疫原性。疫苗是通过不同途径给药的,包括肌内,皮下或鼻内给药,并将结果与​​单独使用Tat或明矾佐剂递送的Tat进行免疫比较。数据表明,在全身和/或粘膜免疫后,纳米球和微球/ Tat制剂是安全的,可在小鼠中诱导强大而持久的细胞和体液反应。这些递送系统可能具有针对HIV的新型基于Tat蛋白的疫苗的巨大潜力,并有望用于其他基于蛋白的疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号